|
WO2021067465A1
|
|
Treating spondyloarthritic and psoriatic conditions with upadacitinib
|
|
WO2021055907A1
|
|
Treatment of cancer
|
|
WO2021041608A1
|
|
System and method of multi-drug delivery
|
|
WO2020232214A1
|
|
Treating acute myeloid leukemia (aml) with mivebresib, a bromodomain inhibitor
|
|
JP2020172484A
|
|
Solid pharmaceutical compositions for treating hcv
|
|
WO2020106835A1
|
|
Methods for treating acute hcv
|
|
WO2020102628A1
|
|
Pharmaceutical formulations for subcutaneous administration
|
|
CA3110519A1
|
|
Process for manufacturing pibrentasvir active drug substance
|
|
AU2019315522A1
|
|
Dosing regimens for elagolix
|
|
WO2020023459A1
|
|
Elagolix sodium compositions and processes
|
|
EP3813760A1
|
|
Medicine container, method of assembling the container, and method of manufacturing the container
|
|
US2019374722A1
|
|
Injection device with end of dose indicator
|
|
WO2019222331A1
|
|
Treating solid tumors with bromodomain inhibitors
|
|
US2021017222A1
|
|
Selective reduction of antibodies
|
|
US2021023234A1
|
|
Ectonucleotide pyrophosphate-phosphodiesterase (enpp) conjugates and uses thereof
|
|
TW202002952A
|
|
ABBV-621 in combination with anti-cancer agents for the treatment of pancreatic cancer
|
|
WO2019178438A1
|
|
Abbv-621 in combination with anti-cancer agents for the treatment of cancer
|
|
TW201940483A
|
|
Inhibitors of tyrosine kinase 2 mediated signaling
|
|
CN112135631A
|
|
Combination of a selective BCL-2 inhibitor with an anti-PD-1 or anti-PD-L1 antibody for cancer treatment
|
|
JP2019069170A
|
|
Systems and methods for tubing delivery
|
